Howard M, Muchamuel T, Andrade S, Menon S
DNAX Research Institute, Palo Alto, California 94304.
J Exp Med. 1993 Apr 1;177(4):1205-8. doi: 10.1084/jem.177.4.1205.
Interleukin 10 (IL-10) decreases production of IL-1, IL-6, and tumor necrosis factor alpha (TNF-alpha) in vitro, and neutralization of IL-10 in mice leads to elevation of the same monokines. We test here whether this monokine-suppressing property of IL-10 confers on it the capacity to protect mice from lipopolysaccharide-induced shock, a monokine-mediated inflammatory reaction. A single injection of 0.5-1 microgram of recombinant murine IL-10 reproducibly protected BALB/c mice from a lethal intraperitoneal injection of endotoxin. This result was obtained whether the IL-10 was administered concurrently with, or 30 min after the injection of endotoxin. The protective effect of IL-10 was reversed by prior injection of neutralizing anti-IL-10 antibodies, and correlated with a substantial decrease in endotoxin-induced TNF-alpha release. These data implicate IL-10 as a candidate for treatment of bacterial sepsis, and more generally as an effective antiinflammatory reagent.
白细胞介素10(IL-10)在体外可降低IL-1、IL-6和肿瘤坏死因子α(TNF-α)的产生,在小鼠体内中和IL-10会导致相同单核因子水平升高。我们在此测试IL-10的这种单核因子抑制特性是否赋予其保护小鼠免受脂多糖诱导的休克(一种单核因子介导的炎症反应)的能力。单次注射0.5 - 1微克重组鼠IL-10可重复性地保护BALB/c小鼠免受致死剂量的腹腔内注射内毒素。无论IL-10是与内毒素同时注射还是在内毒素注射后30分钟注射,均可获得此结果。IL-10的保护作用可被预先注射的中和抗IL-10抗体逆转,且与内毒素诱导的TNF-α释放的显著减少相关。这些数据表明IL-10是治疗细菌性败血症的候选药物,更广泛地说,是一种有效的抗炎试剂。